Tear fluid is known to contain many different hormones with relevance for ocular surface homeostasis. We studied the presence and functional role of insulin-like factor 3 (INSL3) and its cognate receptor RXFP2 (relaxin/insulin-like family peptide receptor 2) at the ocular surface and in tears. Expression of human INSL3 and RXFP2 was determined in tissues of the ocular surface and lacrimal apparatus; in human corneal (HCE), conjunctival (HCjE), and sebaceous (SC) epithelial cell lines; and in human tears by RT-PCR and ELISA. We investigated effects of human recombinant INSL3 (hrINSL3) on cell proliferation and cell migration and the influence of hrINSL3 on the expression of MMP2, -9, and -13 and TIMP1 and -2 was quantified by real-time PCR and ELISA in HCE, HCjE, and SC cells. We used a C57BL/6 mouse corneal defect model to elucidate the effect of topical application of hrINSL3 on corneal wound healing. INSL3 and RXFP2 transcripts and INSL3 protein were detected in all tissues and cell lines investigated. Significantly higher concentrations of INSL3 were detected in tears from male vs. female volunteers. Stimulation of HCE, HCjE, and SC with hrINSL3 significantly increased cell proliferation in HCjE and SC and migration of HCjE. Treatment with hrINSL3 for 24 hours regulated MMP2, TIMP1, and TIMP2 expression. The local application of hrINSL3 onto denuded corneal surface resulted in significantly accelerated corneal wound healing in mice. These findings suggest a novel and gender-specific role for INSL3 and cognate receptor RXFP2 signaling in ocular surface homeostasis and determined a novel role for hrINSL3 in corneal wound healing. (Endocrinology 154: 2034 -2045, 2013) T he integrity of the ocular surface is maintained as a result of complex endocrine regulatory mechanisms (1-3). It is yet unknown whether the hormone insulin-like factor 3 (INSL3) and its cognate receptor relaxin/insulinlike family peptide receptor 2 (RXFP2) are present at the ocular surface or in the tear film. INSL3 consists of an Aand B-chain, and the B-chain is required for a high-affinity interaction with RXFP2 (4 -6). This interaction of INSL3 with RXFP2 involves INSL3 residues His-B12, Arg-B16, Val-B19, Arg-B20, and Trp-B27 in mouse and human (7-9). Phylogenetically, the G protein-coupled receptor RXFP2 belongs to the class C of leucine-rich G proteincoupled receptors (LGR) and was formerly named LGR8 (4, 7). Binding of INSL3 to RXFP2 leads to an increase of cAMP levels in gubernacular cells (10), whereas in testicular germ cells and oocytes, cAMP levels are decreased (11). INSL3 and its receptor are best known for their role in testis descent (12). However, in recent years, the importance of the interaction of INSL3 with RXFP2 in normal and diseased conditions other than reproduction (13-16) has been recognized, ie, bone homeostasis (17) Abbreviations: BrdU, 5-bromo-2Ј-deoxyuridine; DMSO, dimethylsulfoxide; DNase, deoxyribonuclease; ECM, extracellular matrix; hrEGF, human recombinant epidermal growth factor; hrINSL3, human recombinant INSL3; INSL3, insulin-like factor 3; MMP, matrix metalloproteinase; RNase, ribonuclease; RXFP2, relaxin/insulin-like family peptide receptor 2; TIMP, tissue inhibitor of metalloproteinase.
T
he integrity of the ocular surface is maintained as a result of complex endocrine regulatory mechanisms (1) (2) (3) . It is yet unknown whether the hormone insulin-like factor 3 (INSL3) and its cognate receptor relaxin/insulinlike family peptide receptor 2 (RXFP2) are present at the ocular surface or in the tear film. INSL3 consists of an Aand B-chain, and the B-chain is required for a high-affinity interaction with RXFP2 (4 -6) . This interaction of INSL3 with RXFP2 involves INSL3 residues His-B12, Arg-B16, Val-B19, Arg-B20, and Trp-B27 in mouse and human (7) (8) (9) . Phylogenetically, the G protein-coupled receptor RXFP2 belongs to the class C of leucine-rich G proteincoupled receptors (LGR) and was formerly named LGR8 (4, 7) . Binding of INSL3 to RXFP2 leads to an increase of cAMP levels in gubernacular cells (10) , whereas in testicular germ cells and oocytes, cAMP levels are decreased (11) . INSL3 and its receptor are best known for their role in testis descent (12) . However, in recent years, the importance of the interaction of INSL3 with RXFP2 in normal and diseased conditions other than reproduction (13) (14) (15) (16) has been recognized, ie, bone homeostasis (17) and cancer (18 -21) . INSL3 enhances cell motility (21) and causes the increased production of cathepsin-L and cathepsin-D, which is associated with enhanced elastinolytic activity of human thyroid cancer cells (22) . In osteoblasts, INSL3 induces a dose-dependent increase in cell proliferation (23) and stimulates the differentiation of osteoblasts capable of mineralizing the extracellular matrix (24) . Despite this progress, the influence of INSL3 on other mechanisms involving the remodeling and turnover of the extracellular matrix (ECM) is currently unknown.
Under physiological conditions, matrix metalloproteinases (MMPs) and their physiological antagonists, the tissue inhibitors of metalloproteinases (TIMPs) are closely involved in the regulation of matrix dynamics at the ocular surface (25) . The maintenance and repair of the physiological barriers of the anterior eye depend on the ability of different cell types of the ocular system to respond dynamically with appropriate cell migration, proliferation, and MMP/TIMP induction to the ever-changing conditions at the ocular surface (26, 27) . In the present study, we characterized the expression of INSL3 and its receptor RXFP2 in human tissues and cell lines derived from the ocular surface. Amniotic membranes used by clinicians as a bandage for ocular surface injuries are a known source of INSL3 and served as a control (14) . We determined the potential role of INSL3 on cell proliferation, migration, and ECM remodeling in cultured human corneal (HCE), conjunctival (HCjE), and sebaceous (SC) cell lines. In addition to the in vitro experiments, we investigated the effect of human recombinant INSL3 (hrINSL3) on corneal lesions in mice as we described previously (28) . Employing a corneal defect mouse model, we identified hrINSL3 as a novel and highly effective endocrine factor capable of enhancing re-epithelialization of corneal wounds.
Materials and Methods

Experimental animals
All animals in the present study were treated in accordance with the Association for Research in Vision and Ophthalmology Resolution on the Use of Animals in Ophthalmic and Vision Research and the recommendations of the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The experiments had received governmental approval. Ten-week-old female C57BL/6 mice were used for all experiments in this study. The animals were obtained from Harlan Laboratories (Venray, The Netherlands) and kept under normal controlled laboratory conditions with a 12-hour light, 12-hour dark cycle.
Tissues and cell lines
The study was conducted in compliance with institutional review board regulations for human and animal ethics, informed consent regulations, and the provisions of the Declaration of Helsinki. ) were seeded into 25-cm 2 flasks and cultured in Sebomed basal medium (Biochrom) containing 10% fetal calf serum and 0.1 mg/mL human recombinant epithelial growth factor (hrEGF) (Sigma, Steinheim, Germany). At confluency, cells were exposed to different concentrations (100 and 500 ng/mL) of hrINSL3 (Phoenix Pharmaceuticals, Burlingame, California) for 6 and 24 hours in serum-free DMEM (HCE and HCjE) or Sebomed basal medium (SC). Cell lines were cultured and experimental procedures were performed under normoxic conditions (21% O 2 , 5% CO 2 ).
Culture of primary corneal fibroblasts
Scleral rings were obtained from the Department of Ophthalmology, Martin Luther University Halle-Wittenberg, Germany, and preserved in DMEM for transportation. Scleral tissue was removed from the limbus with a scalpel. Once the corneal endothelium and epithelium had been removed, the stromal tissue was cut into pieces, transferred into 25-cm 2 flasks, and cultured in DMEM containing 10% fetal calf serum, 50 g/mL streptomycin, and 50 IU/mL penicillin (both from Sigma). Fibroblasts were used for RT-PCR analysis and cell proliferation assays.
RNA preparation and cDNA synthesis
For conventional RT-PCR, tissue biopsies of lacrimal gland, conjunctiva, cornea, and nasolacrimal duct were crushed in an agate mortar under liquid nitrogen and then homogenized with a Polytron homogenizer. Total RNA was isolated using the RNeasy kit (QIAGEN, Hilden, Germany). Crude RNA was purified with isopropanol and repeated ethanol precipitation, and contaminating DNA was destroyed by digestion with ribonu-clease (RNase)-free deoxyribonuclease (DNase) I (30 minutes at 37°C; Boehringer, Mannheim, Germany). Additional incubation with RQ1-RNase-free DNase (Promega, Mannheim, Germany) was conducted on purified RNA to exclude contamination by genomic DNA. Upon treatment, DNase was heat denatured for 10 minutes at 65°C. To further exclude genomic amplifications, PCR was performed with specific DNA primers for INSL3 and RXFP2 as well as 18S rRNA, which all spanned at least 1 intron. We did not observe PCR amplification using total RNA as a template. Five hundred nanograms of total RNA were used for each cDNA reaction. The cDNA was generated with 50 ng/L (20 pmol) oligo-dT 15 
RT-PCR analysis
RT-PCR amplifications were carried out with 2 L cDNA in a final volume of 20 L containing 0.15 L Taq polymerase, 1 L 50mM MgCl 2 , 2 L PCR buffer, 0.5 L dNTP, and 0.5 L forward/reverse primer mix (synthesized at MWGBiotech AG, Ebersberg, Germany), using the following primer combinations: INSL3, forward 5Ј-cagagatgcgtgagaagttgtgc-3Ј and reverse 5Ј-tcagtagggacagagggtcagc-3Ј; RXFP2, forward 5Ј-tgcacagagagcacagcagaatggctc-3Ј and reverse 5Ј-ggacagtgcaacccgatgtgaaagacc-3Ј; and 18S rRNA, forward 5Ј-actcaacacgggaaacctcacc-3Ј and reverse 5Ј-cgctccaccaactaagaacgg-3Ј. After 3 minutes of heat denaturation at 94°C, the PCR cycle consisted of: 1) 94°C for 30 seconds; 2) 68°C (INSL3), 65°C (RXFP2), or 55°C (18S) for 45 seconds each; and 3) 72°C for 1 minute. For each primer pair, 40 cycles were performed and a final elongation step of 72°C for 7 minutes completed the PCR run. Ten microliters of the PCR was loaded onto a 1% agarose gel, and the expected amplicons at 317 base pairs (bp) for INSL3, 240 bp for RXFP2, and 111 bp for 18S rRNA were visualized by ethidium bromide staining. Base pair values were compared with gene bank data, and PCR products were confirmed by BigDye sequencing (Applied Biosystems, Foster City, California).
Real-time RT-PCR for MMP2, MMP9, MMP13, TIMP1, and TIMP2
Samples were analyzed by real-time RT-PCR using an Opticon 2 system (MJ Research, Waltham, Massachusetts). Reactions were performed using SYBR green master mix (Applied Biosystems, Darmstadt, Germany) as a double-stranded DNAspecific fluorescent dye, with the appropriate primer sets: MMP2, forward 5Ј-ggcctctcctgacattgacctt-3Ј and reverse 5Ј-ggcctcgtataccgcatcaatc-3Ј; MMP9, forward 5Ј-gggcttagatcattcctcagtg-3Ј and reverse 5Ј-gccattcacgtcgtccttat-3Ј; MMP13, forward 5Ј-agaccccaaccctaaacatccaaaaac-3Ј and reverse 5Ј-ttaaaaacagctccgcatcaacct-3Ј; TIMP1, forward 5Ј-acttccacaggtcccacaac-3Ј and reverse 5Ј-agccacgaaactgcaggtag-3Ј; TIMP2, forward 5Ј-gagcctgaaccacaggtacca-3Ј and reverse 5Ј-aggagatgtagcacgggatca-3Ј; and 18S rRNA, forward 5Ј-actcaacacgggaaacctcacc-3Јand reverse 5Ј-cgctccaccaactaagaacgg-3Ј. The 18S rRNA was used because its expression was not influenced by any of the mediators investigated. PCR was initiated with 2 minutes at 50°C, followed by 1.5 minutes at 95°C. The program continued with 30 cycles of 20 seconds at 95°C and 60 seconds at 60°C. Each assay included duplicates of each cDNA sample and a nontemplate negative control for MMP2, MMP9, MMP13, TIMP1, and TIMP2. The cycle threshold (CT) parameter is defined as the cycle number at which fluorescence intensity exceeds a fixed threshold. Relative amounts of mRNA expression were calculated using the ⌬⌬CT method (32) . The expression of 18S rRNA was used to normalize samples for the amount of cDNA used per reaction. To confirm the amplification, the resulting real-time PCR products were analyzed by dissociation curves and amplicons were confirmed by Big Dye termination sequencing. Three replicates from 3 independent experiments were combined for the calculation of the results.
INSL3 ELISA
INSL3 released in tears of healthy volunteers and INSL3 concentrations in samples from human cadaveric cornea, eyelid, lacrimal gland, nasolacrimal ducts, and prostate as well as 5 samples of amniotic membranes were measured with an ELISA, purchased from Phoenix Pharmaceuticals. The assay was performed according to the manufacturer's instructions. Schirmer strips used to collect the tears were stored at Ϫ20°C until processed. Strips from both eyes were pooled and centrifuged to extract the tears. The samples were centrifuged at 13 000 rpm for 30 minutes. Total protein content was measured with a protein assay (Bio-Rad, München, Germany). rhINSL3 at the concentrations of 0, 0.01, 0.1, 1, 10, and 100 ng/mL served as the standard. The detection limit of this assay was 0.01 ng/mL of INSL3. Concentrations were calculated in relation to total protein concentrations.
MMP2, TIMP1, and TIMP2 ELISA
Supernatants from 24-hour stimulation experiments were investigated for MMP2, TIMP1, and TIMP2 protein levels with specific ELISA kits (RayBiotech, Norcross, Georgia). The assays were performed according to the manufacturer's instructions. Total protein content was measured with a protein assay (BioRad, Munich, Germany). Human recombinant MMP2, TIMP1, and TIMP2 served as standards. Concentrations were calculated in relation to total protein concentrations. Three replicates from 3 independent experiments were combined for the calculation of the results.
Cell proliferation assay
A colorimetric 5-bromo-2Ј-deoxyuridine (BrdU) cell proliferation ELISA (Roche Diagnostics, Mannheim, Germany) was used according to the manufacturer's instructions. Briefly, on the day of assay, 10M BrdU labeling solution was added to each well of a 96-well plate, except for negative controls that received no BrdU. Cells were incubated for 18 hours at 37°C in a watersaturated CO 2 incubator. Plates were drained and blocked with 200 L/well of precooled ELISA fixative for 30 minutes at Ϫ20°C. After decanting, 100 L of anti-BrdU-peroxidase was added to each well and dishes were incubated for 30 minutes at 37°C. Plates were drained, washed, and incubated with 100 L/ well of anti-BrdU working solution for 30 minutes at 37°C. Finally, 100 L of peroxidase substrate were added to each well, incubated for 1 minute on a shaker at 300 rpm, and absorbance was measured within 5 minutes at 405 nm in an ELISA reader (SLT LAB Instruments, Crailsheim, Germany).
Migration assay
In vitro wound modeling was performed using a scratch assay. Confluent monolayers of HCE and HCjE on glass coverslips in 6-well plates were scratched with a 200-L plastic pipette tip to create a cell-free area. Cultures were gently washed 3 times with DMEM F12 to remove loose cells. DMEM was added with or without 100 ng/mL rhINSL3, and cells were incubated for 24 hours in a CO 2 incubator. In addition, cultures treated with 100 ng/mL rhINSL3 were also treated for 24 hours with 5 g/mL mitomycin C or 5M cytochalasin B (both from Sigma). Mitomycin C was dissolved in dimethylsulfoxide (DMSO) (Sigma). For comparison, we used hrEGF, which has known promigratory properties on epithelial cells. After washing, cells were fixed for 5 minutes in 4% paraformaldehyde. Repeated washing was followed by staining of the cells with hematoxylin and eosin. Glass coverslips were examined with an Axiophot microscope (Zeiss, Jena, Germany). Nine fields of each scratch area were photographed, and the cell-free width was determined. For comparison, 3 slides were stained at time 0 and photographed. The average width of the scratch closure area was calculated. Experiments were repeated twice.
Corneal wound in vivo experiments
To produce corneal wounds, mice (n ϭ 30) were anesthetized by an ip injection of ketamine (90 mg/kg body weight, Ketavet 100 mg/mL; Pharmacia, Berlin, Germany) and xylazine (6 mg/kg body weight, Rompun 2%; Beyer, Leverkusen, Germany). Conjucain EDO eye drops (Bausch & Lomb, Berlin, Germany) were applied to the cornea as a topical anesthetic for pain relief postoperatively. Corneal wounds were produced as described previously (28) . In brief, on the right eye of each animal, an alkalisoaked (0.5M NaOH) filter paper disk (Whatman filter paper, grade 41, 20 -25 m; Dassel, Germany) of 2 mm in diameter was placed on the central surface of the cornea for 2 minutes followed by rinsing in 0.9% sterile saline (Fresenius Kabi, Bad Homburg, Germany). The left eye of each mouse was left untreated and served as a control for normal cornea. After producing a defined central corneal ulcer of 2 mm in diameter, the corneas were allowed to partially heal in vivo for up to 6 hours. At the end of this period, mice were killed and the eyes were enucleated with an anatomical forceps (Geuder, Heidelberg, Germany). Each eye was transferred to a well that contained a 3-mm-thick dental wax layer at the bottom. Eyes were pinned to the wax with a sterile needle (27-gauge ϫ 3/4 in Sterican; B. Braun, Melsungen, Germany) adjusting the corneal surface to face upward. Each well received 1 mL of DMEM/F12 medium supplemented with amphotericin B (2.5 g/mL; Biochrom, Berlin, Germany), 50 IU/mL penicillin, and 50 g/mL streptomycin to cover the eyes completely. The eyes were randomly assigned to a control group, a 30 ng/mL INSL3 group, and a 100 ng/mL INSL3 group (10 eyes in each group). Corneal wounds in the control group received 1 mL of medium. Treatment groups received 30 or 100 ng/mL INSL3 in medium. The eyes were maintained in a tissue culture incubator (Heraeus, Hanau, Germany) at 37°C (5% CO 2 and 21% O 2 ). To monitor the corneal healing process, photos were taken by a Micron III unit (Phoenix Research Laboratories, Pleasanton, California) generating a blue light at 0, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 , and 84 hours after alkali-induced corneal wounding, respectively. The corneal wounds were visualized by applying sodium fluorescein eye drops (Fluoreszein SE Thilo; Alcon, Fort Worth, Texas). On the photographs, the area of corneal defect was evaluated using the SigmaScan Pro version 5 software (SPSS, Inc, Chicago, Illinois).
Statistical analysis
Data are expressed as mean Ϯ SEM. After proving normal distribution using the Kolmogorov-Smirnov test, we performed 1-way ANOVA statistics. For the interpretation of the results, we used either the Bonferroni or the Games-Howell post hoc test depending on Levene's test for homogeneity of variances. As nonparametric statistics, we performed Mann Whitney U test. To compare the corneal epithelial healing after alkali-induced wounds between control group and the 30 ng/mL INSL3 and 100 ng/mL INSL3 groups, the wound areas were measured at different time points and Kaplan-Meier analysis was performed. The terminal event was defined as complete healing of the corneal wounds. Statistical significance among groups was analyzed by the log-rank test. The IBM SPSS Statistics 18 (IBM Deutschland GmbH, Ehningen, Germany) for Windows software package was used for the statistical analysis. P Ͻ .05 was considered statistically significant.
Results
Transcripts for RXFP2, but not INSL3, are expressed at the ocular surface and in the lacrimal apparatus
Amplicons specific for INSL3 (317 bp) were infrequently detected in lacrimal gland, eye lids, conjunctiva, cornea, and nasolacrimal ducts (Figure 1 ). Primary corneal fibroblasts were devoid of INSL3 transcript. Specific amplicons for INSL3 were regularly observed in SC, HCjE, and HCE cells. A single specific RXFP2 amplicon at the expected size of 240 bp was detected in the lacrimal gland, eye lids, conjunctiva, cornea, nasolacrimal ducts, and primary corneal fibroblasts (Figure 1) . SC, HCjE, and HCE cells also presented RXFP2 amplicons. In all tissues and cell lines investigated, 18S rRNA served as internal control for each sample.
INSL3 is present at the ocular surface and reveals a gender-specific distribution in tears An INSL3-specific ELISA was used to quantify INSL3 concentrations in vivo in different tissues at the ocular surface and in the tear fluid of healthy volunteers. INSL3 protein was detectable in the lacrimal gland, eyelid, conjunctiva, cornea, and nasolacrimal ducts as well as in amniotic membrane and prostate used as control tissues (Table 1). The highest INSL3 concentration was measured in the cornea (up to 28.14 pg/mL), and the lowest INSL3 concentration was observed in nasolacrimal duct tissues (2.72 pg/mg); however, the number of samples investigated was limited (cornea, n ϭ 2; nasolacrimal ducts, n ϭ 1). INSL3 in tears was below the detection limit in 3 of 5 female donors ( Table 2 ). The detectable concentrations in the female tears varied from 2.09 to 42.23 pg/mg total protein. In contrast, tears collected from male volunteers contained significantly higher amounts of INSL3 (P ϭ .028) in all samples investigated (65.89 Ϯ 33.85 pg/mg total protein). Cell supernatants derived from SC and HCjE contained high concentrations of secreted INSL3, whereas levels of secreted INSL3 were lower in HCE cells (Table 3) .
INSL3 causes weak proliferation in SC and HCjE cells
A small increase in proliferation of SC cells by 1.23-fold was detected in BrdU assays upon 24 hours stimulation with 100 ng/mL rhINSL3, and no further increase was observed with 500 ng/mL rhINSL3 (Figure 2) . A 1.5-and 1.6-fold increase in proliferation at 100 and 500 ng/mL rhINSL3, respectively, was detected in HCjE cells. HCE cells showed a 1.2-fold increase in growth at 100 ng/mL rhINSL3 without reaching statistical significance, whereas 500 ng/mL rhINSL3 had no effect. INSL3 had no effect on the proliferation of primary corneal fibroblasts (data not shown).
INSL3 promotes migration of HCjE
HCjE cells stimulated with 100 ng/mL rhINSL3 for 24 hours showed a significant higher scratch closure rate as compared with untreated cells ( Figure 3C ). To determine whether this effect was the result of increased proliferation and/or migration, cells were treated with inhibitor of migration cytochalasin B and the proliferation inhibitor mitomycin C. In the presence of cytochalasin B, negligible cellular movement into the scratch area was observed and rhINSL3 failed to induce a scratch closure. The proliferation inhibitor mitomycin C had no noticeable effect on scratch closure. Thus, the main effect of INSL3 in scratch closure pertained to increased cell migration. The motilityenhancing effect of promigratory hrEGF was comparable to the closure rate of HCjE cells treated with 100 ng/mL rhINSL3. The addition of an equivalent concentration of the mitomycin C solvent DMSO for 24 hours alone re- sulted in a negligible change in migration (data not shown). HCE cells stimulated with 100 ng/mL rhINSL3 for 24 hours showed elevated migration rates compared with untreated cells, but this did not reach statistical significance, and the migratory response was significantly weaker in comparison with HCE cells when hrEGF (30 ng/mL) was used ( Figure 3F ). Treatment of HCE with the motility inhibitor cytochalasin B or the proliferation inhibitor mitomycin C had no significant effect on scratch closure times. Addition of DMSO solvent alone for 24 hours resulted in no significant change in migration rate (data not shown).
INSL3 induces specific MMP and TIMP transcripts in SC, HCjE, and HCE
Real-time PCR analysis of SC cells treated with rhINSL3 at 100 ng/mL for 24 hours revealed a 1.7-fold induction in transcript levels for TIMP2 when compared with untreated controls ( Figure 4A ). Stimulation with hrINSL3 showed a tendency to induce MMP2 and TIMP1 mRNA expression, but this was not statistically significant. Higher amounts of rhINSL3 (500 ng/mL) had no significant effect on mean MMP2 and TIMP1/2 mRNA levels. Shorter exposure time (6 hours) had no effect on mean MMP2, TIMP1, and TIMP2 mRNA concentrations (data not shown). No significant changes in MMP9 and MMP13 transcript levels were observed with rhINSL3 at all concentrations and time points tested (data not shown). Stimulation with 100 ng/mL rhINSL3 resulted in a significant increase in TIMP2 in SC cell supernatants ( Figure  4D ).
HCjE stimulated with 100 ng/mL rhINSL3 for 24 hours revealed an induction by 1.97-fold and 2.64-fold of MMP2 and TIMP2 transcript levels, respectively ( Figure  4B) . A 6-hour stimulation with rhINSL3 had no effect on MMP2 and TIMP2 mRNA expression (data not shown). Expression of MMP9, MMP13, and TIMP1 was not significantly affected by rhINSL3 at any time point and concentration tested (data not shown). In HCjE cell supernatants, TIMP1 and TIMP2, but not MMP2, protein levels were increased when stimulated for 24 hours with 500 ng/mL rhINSL3 ( Figure 4E ).
HCE cells showed an induction of TIMP1 mRNA by up to 1.8-fold after 24 hours stimulation with 100 ng/mL rhINSL3 ( Figure 4C ), whereas the increase in MMP2 expression was not statistically significant. Expression of TIMP2, MMP9, and MMP13 was not affected by rhINSL3 at any time point and concentration tested, and treatment with rhINSL3 for 6 hours also had no significant effect on MMP/TIMP mRNA expression in HCE (not shown). We measured no significant difference in the MMP2, TIMP1, and TIMP2 protein concentrations in HCE cell supernatants ( Figure 4F ).
INSL3 promotes efficient re-epithelialization of corneal ulcers
Representative images of healing corneas are provided in Figure 5A . For better visualization, dotted lines indicate the wound area. The alkali-burned area decreased over time in all 3 treatment groups with the lowest healing tendency in the control group and the fastest defect re- covery in the 100 ng/mL rhINSL3 group. Although control eyes showed a healing tendency, these eye defects did not heal completely within 86 hours ( Figure 5B ). When treated with 30 ng/mL rhINSL3, 40% of the eyes healed completely. All eyes receiving treatment with 100 ng/mL rhINSL3 showed complete closure of corneal defects within 72 hours. Kaplan-Meier corneal wound healing curves with the log-rank test revealed a statistically significant difference between the control and 100 ng/mL rhINSL3 group (P ϭ .002) ( Figure 5B ). Thus, the topical application of hrINSL3 at 100 ng/mL onto corneal ulcers produced by alkaline injury significantly accelerated the re-epithelialization of the corneal wounds.
Discussion
This is the first report on the presence and functional role of human INSL3 and its cognate receptor RXFP2 at the ocular surface and in the lacrimal apparatus. The detection of transcripts for RXFP2 in the lacrimal gland, eyelid, conjunctiva, cornea, nasolacrimal ducts, and primary corneal fibroblasts identified the ocular surface and the lacrimal apparatus as novel physiological target tissues of the actions of INSL3. We identified INSL3 ligand to be present at low concentrations in tissues of the ocular surface. Our inability to detect INSL3 transcripts in some tissue samples that proved positive for INSL3 protein may be explained by the fact that ocular tissues were obtained from cadaveric specimens, and RNA degradation may have accounted for reduced detection sensitivity in these tissues. Intriguingly, tear fluid contained high levels of INSL3 protein. This was not the result of a simple accumulation of INSL3 produced by the ocular tissues because INSL3 concentrations measured in tear fluid were up to 10-fold higher than INSL3 levels determined at the ocular surface. In young healthy males and nonpregnant females, we consistently found tear fluid collected from males to contain markedly higher levels of INSL3 (Table 2) . Our findings of a sex difference in INSL3 content in tears corresponds with previous findings that reported highest INSL3 blood serum levels of up to 1.3 ng/mL in young men (33) . In contrast, adult nonpregnant women were reported to have very low to undetectable INSL3 serum levels (34). Our findings would imply 2 intriguing scenarios for the INSL3-RXFP2 ligand receptor system in the human eye. First, tissues of the ocular surface and lacrimal apparatus are a site of INSL3 production that, independent of sex, maintains a low level of INSL3 at the ocular surface. Second, tear fluid provides an additional rich source of INSL3 and the higher concentration of INSL3 in males suggests an as yet unknown mechanism by which INSL3 is concentrated in the tear film. INSL3 may be transported to the ocular surface via the blood stream and secreted into the tear film. Interestingly, a similar finding was described for the close structural relative insulin in tear fluid (35) . We cannot exclude the possibility that processing of INSL3 at the ocular surface may account for the differences in INSL3 levels detected at the ocular surface and in tears. INSL3 is first synthesized as a preprohormone comprised of a signal sequence followed by a B-C-A domain configuration (36) . The signal sequence and C domain peptide are removed during processing of the mature INSL3 peptide. The antiserum used in the ELISA may not be capable of detecting immature INSL3 proforms present in the tissues and cell lines investigated, whereas the fully processed mature INSL3 may be quantitatively secreted into the tear film and become readily detectable by the INSL3 ELISA. Future studies employing Western blot and mass spectroscopy analysis may clarify this point. Stimulation of human and mouse osteoblasts with rh INSL3 has previously been shown to induce a dose-dependent increase in cell proliferation (23) . We employed 3 distinct human ocular cell models representing conjunctival (HCjE), corneal epithelial (HCE), and facial seba- At this point in time, we can only speculate as to why rhINSL3 had less effect at 500 ng/mL than at 100 ng/mL. We cannot exclude the possibility that the RXFP2 is desensitized and/or internalized at higher INSL3 concentrations as has been described for other G protein-coupled receptors (37) . Differences in sex hormone levels, eg, androgen deficiency and menopause, are hypothesized to correlate with meibomian gland disease, a subtype of dry eye syndrome (38) . Sex steroid hormones, such as androgens, are known to control the development, differentiation, and lipid production of sebaceous glands throughout the body. There is evidence that these steroid hormones have similar effects on the meibomian glands (38) . Intriguingly, RXFP2 signaling has an important role in mediating androgen actions (39, 40) . The mild growth-promoting action of INSL3 we observed with SC cells is expected to translate into enhanced sebum production, as the cells themselves become the sebum. Thus, INSL3 may affect the composition of the tear film by improving the lipid layer that acts as a seal to reduce tear fluid evaporation. Currently, information is lacking on INSL3 concentrations in dry eye syndrome. Intriguingly, dry eye syndrome is more prevalent in women than in men (2) , and this inversely correlates with the gender-specific differences in INSL3 content in tears reported by us. However, more work is required to clarify the relationship between RXFP2 signaling and the common dry eye syndrome.
Clinical treatment of ulcers and injuries of the ocular surface, such as corneal ulceration, conjunctival disorders, or chemical and thermal burns, are often treated by amniotic membrane transplantation (41) . Such amniotic membranes likely deliver a plethora of growth factors and serve as a matrix for epithelial cells migrating into a defective area (42) . The amniotic epithelial cell layer has previously been shown to be a source of INSL3 (14), and we were able to confirm these results ( Table 1 ). The migration of ocular surface cells into sites of ocular surface injury is an essential mechanism of the corneal/conjunctival wound healing response (28) . We observed that INSL3 markedly increased the migration and proliferation as well, although to a lesser extent, of HCjE cells. However, in vitro investigations showed only a mild but not significant increase in HCE migration and proliferation, suggesting that the differences in biological responses in HCE and HCjE cells upon exposure to INSL3 may result from the activation of different signaling pathways in these cell types. Under physiological conditions, these cells are important for the restoration of an intact ocular surface (25) . Although factors other than INSL3 can act as more potent stimulators of proliferation in HCjE and HCE cells, INSL3 may serve a prominent role in promoting the increased in vivo migration of corneal epithelial cells into denuded ocular surfaces. We recently showed Figure 5 . Corneal re-epithelialization after alkali burning is accelerated by treatment with 30 and 100 ng/mL of rhINSL3. A, Photographic images showing representative fluorescein-stained corneal wounds of control, 30 ng/mL INSL3, and 100 ng/mL rhINSL3 groups at different time points during the healing process. The edges of the wound areas are marked with a white dotted line, and the enclosed area was quantified using the software Sigma Scan Pro version5.0. B, Kaplan-Meier curves show the probability of corneal wound healing at different time points in the following 3 groups: control, 30 ng/mL rhINSL3, and 100 ng/mL rhINSL3. Censored cases are indicated by small vertical tick marks. Corneal wound healing was significantly enhanced by local application of INSL3 on the wound surface.
that INSL3 enhances tumor cell motility in different cancer cell models (20, 21) . Our present results suggest that INSL3 positively affects corneal and conjunctival epithelial repair by inducing a combined mild proliferative and potent promigratory action in epithelial cells at the ocular surface.
The structural close relative relaxin 2 is well known for its ability to modify the composition of the ECM by altering the synthesis/secretion of collagen and the expression of members of the MMP and TIMP families (43) (44) (45) (46) . MMPs are a family of tissue-degrading enzymes and play an important role, eg, in tissue remodeling and wound healing. MMPs and TIMPs are known to have multiple functions in wound healing at the ocular surface as well as in dry eye disease, corneal neovascularization, the development of corneal ulcers, and in pterygium formation (47) . MMP2 is expressed in healthy cornea and up-regulated during wound healing (48) , suggesting an important role for MMP2 during physiological ECM turnover and wound healing of the cornea (49) . Currently, information is lacking on the ability of INSL3 to induce the expression or modify the catalytic activity of the MMP/TIMP system. We report here elevated MMP2 mRNA levels in the presence of INSL3 in all 3 cell lines investigated (SC, HCjE, and HCE), suggesting a modulatory role for INSL3 on the ECM at the ocular surface. However, the findings at the mRNA level did not translate into increased MMP2 protein levels in cell supernatants. Besides MMP2, we investigated two other MMP members associated with specific steps of wound healing at the ocular surface. MMP9 has been detected in the basal epithelial cell layer of the healing cornea and appears to play a role in the formation of the new epithelial lining after corneal wounding (48) . MMP13 has been implicated in the renewal of epithelium at the wounded cornea and is detectable only during wound healing (48) . INSL3 failed to alter the expression of either of these MMP members in HCjE, HCE, and SC cells. The interaction between TIMP1 and TIMP2 with MMP2 and MMP9 renders these MMPs inactive (50) . INSL3 increased the expression of TIMP1 and TIMP2 in the conjunctival epithelial and sebocyte cell line. Interestingly, MMP2 and TIMP1/2 had previously been identified as relaxin targets in different cell types, which may indicate overlapping functions of relaxin and INSL3 in their ability to remodel the ECM (51) . The discrepancies in relative mRNA expression levels as determined by real-time PCR and the level of some soluble proteins detected by ELISA, which was particularly evident for HCjE cells (Figure 4 , B and E), may be explained by the fact that both mRNA and secreted protein data provide information from opposite ends of the transcriptional/translational spectrum. Our real-time PCR data detected only moderate changes in mRNA expression not exceeding a 3-fold up-regulation. The ELISA detected secreted protein, and multiple steps are required within a cell to accommodate this complex process. Thus, it may not be surprising to see a certain level of incongruity when comparing these data sets. Furthermore, MMP2 is expressed as a membrane-anchored proform and requires secreted TIMP2 and MMP14 for further processing into a soluble form, adding yet another layer of complexity (52) . The increased secretion of TIMP1 and TIMP2 observed in HCjE cells upon exposure to high INSL3 (500 ng/mL) concentrations requires additional studies, particularly given the role of both TIMPs during re-epithelialization of the cornea (53) . At the ocular surface, the matrix remodeling activity of INSL3 may provide yet another mechanism by which INSL3 can modulate and protect the ocular microenvironment, eg, by preventing disproportionate epithelial deposition, enzymatic remodeling of the tear fluid, and/ or protecting the ocular surface from the destructive effects of foreign particles. It is tempting to suggest that INSL3 can modulate the activity of distinct signaling pathways in the different cell types at the ocular surface. Delineating these signaling cascades activated by INSL3 in ocular cell types is subject to future studies. The mechanistic insight gained from these studies is likely to provide new therapeutic strategies that include INSL3 for advanced treatment of certain eye diseases.
The results of our in vitro experiments identified INSL3 as a mild growth factor with promigratory and MMP/ TIMP-inducing capacities that were suggestive of a potential protective function of the INSL3-RXFP2 system at the ocular surface. To further elucidate whether INSL3 had a significant impact on the extent and speed of reepithelialization of the injured ocular surface, we employed a well-established corneal defect model in mice (28, 54) . In the presence of hrINSL3, we observed significantly enhanced and INSL3 dose-dependent wound healing rates. However, limitations of our study result from the exclusive use of female mice. Whether there are differences in the wound healing rate between female and male mice is subject to future investigations. Our findings may have broad implications for the development of novel therapeutic strategies for the treatment of frequently occurring injuries to the ocular surface. For example, millions of laser surgeries are performed each year and patients often suffer from delayed epithelial healing, which increases the risk of postoperative haze, infectious keratitis, and ulceration. Ocular application of hrINSL3 may help alleviate these conditions and result in improved and expedited closure of the ocular epithelial layer and rapid relief of adverse symptoms in patients.
In conclusion, we provided evidence for a complex protective role of hrINSL3 at the ocular surface and identified a novel role for hrINSL3 as an effective therapeutic agent in the treatment of corneal ulcerations.
